[29], can augment the anti-inflammatory effects of corticosteroids while minimizing systemic exposure, thereby reducing the risk of infections and other adverse effects
It is also unclear if risk cardiovascular disease risk factors are feasible to predict future CAD in LT recipients
E.LeoneC.VannucchiH
Compared to rituximab, deeper B cell depletion is being explored with antibodies targeting CD20 (obinutuzumab), CD19 (inebilizumab), CD38 (daratumumab), the BAFF receptor (ianalumab), and TACI (telitacicept), as well as proteasome inhibition with bortezomib, all showing promise in IMIDs ( A key limitation of BCDA is the increased infection risk due to prolonged B-cell depletion, concurrent immunosuppressive therapy, and hypogammaglobulinemia ( Despite a plethora of successful targeted biologic therapies with different mechanisms of action, most patients with IMID still do not achieve remission, let alone drug-free remission ( 3 From stem cell therapy to targeted cell therapy for immune mediated inflammatory diseases 3.1 Transition from stem cell therapy to chimeric antigen receptor T cell therapy In contrast to the chronic immune suppression associated with targeted biologic therapies, stem cell treatments, including both mesenchymal stem cell therapy (MSCT) and hematopoietic stem cell therapy (HSCT)present a promising approach for potentially curing IMIDs by reinducing self-tolerance
Increased intraocular pressure as a risk factor in glaucoma The vertebrate eye is a highly dynamic environment where IOP provides the hydrostatic pressure that is necessary for maintaining the shape, growth and optical properties of ocular tissues
